A multicentre study of twice daily acebutolol ('Sectral') in the treatment of hypertension in general practice.
- 1 January 1979
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 6 (1)
- https://doi.org/10.1185/03007997909109398
Abstract
An open multicentre study was carried out under uncontrolled conditions in general practice to investigate the efficacy and acceptability of twice daily acebutolol in patients with mild to severe hypertension. Data from 1007 patients were analyzed. Most (901) had been treated previously with other hypertensive agents before starting on acebutolol. Oral dosages of acebutolol ranged from 200 mg to 1200 mg/day, according to individual requirements, and 331 patients received concomitant therapy, usually with a diuretic, either from the start of therapy or after 4 to 8 weeks. A significant reduction (p less than 0.001) was observed in mean diastolic blood pressure over the 12-week assessment period, and response increased with treatment duration. There were 280 reports of side-effects and 63 patients were withdrawn from the study for this reason.Keywords
This publication has 5 references indexed in Scilit:
- Blockade of isoprenaline‐induced changes in plasma free fatty acids, immunoreactive insulin levels and plasma renin activity in healthy human subjects, by propranolol, pindolol, practolol, atenolol, metoprolol and acebutolol.British Journal of Clinical Pharmacology, 1978
- Suppression of premature ventricular contractions by acebutolol.Circulation, 1977
- An open, multicentre study of acebutolol in hypertensionCurrent Medical Research and Opinion, 1976
- Properties of acebutolol in twenty patients with cardiac arrhythmiasEuropean Journal of Clinical Pharmacology, 1975
- β‐Adrenoceptor blocking properties and cardioselectivity of M & B 17,803ABritish Journal of Pharmacology, 1973